
Opinion|Videos|October 29, 2024
Utilization of 68Gallium PSMA-11 in Clinical Practice
Author(s)Oliver Sartor, MD
Key Takeaways
- 68gallium PSMA-11 gozetotide is essential for prostate cancer imaging but faces production and distribution challenges.
- Expanding production facilities and streamlining regulatory processes could enhance availability.
The panelist discusses how the limited availability of 68gallium PSMA-11 gozetotide in clinical practice poses challenges and suggests potential strategies to increase accessibility, such as expanding production facilities, improving distribution networks, and exploring alternative radiotracers with longer half-lives.
Advertisement
Discuss the availability of use 68gallium PSMA-11 gozetotide in clinical practice. What are potential strategies to increase availability?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
Michael Cookson, MD, discusses new strategies for treatment intensification in prostate cancer
5



















